The study included 32 obese women with newly diagnosed PCOS based on the National Institute of Child Health and Human Development (NICHD) criteria. Participants were randomized to receive either liraglutide (1.2 mg daily) or metformin (1,000 mg twice daily) for 12 weeks. Anthropometric measurements and body composition assessments were conducted using DXA. Blood samples were taken for glucose, insulin, and other metabolic and hormonal analyses before and after treatment. Safety parameters were also assessed. This evidence concerns the gene INS and polycystic ovary syndrome.